Abstract
The purpose of this clinical study was to evaluate the effectiveness of β-tricalcium phosphate (β-TCP) as a
bone graft substitute in maxillary sinus floor elevation.
Sixty one of the one hundred five patients were treated with β-TCP for maxillary sinus floor elevation from
May 2007 to February 2013. Various factors were evaluated over five months following the treatment to
determine the effectiveness of β-TCP for both lateral and crestal approach.
No complication was observed for the crestal approach. Perforation of maxillary sinus membrane was
observed for 4% of lateral approach treatment. However, recovery was alleviated by the use of resorbable
membrane and collagen membrane. Maxillary sinusitis and the leakage of β-TCP were not observed.
The results demonstrated the effectiveness of β-TCP in bone grafting not only through osteoconductivity, but
also biocompatibility, bioresorbability, and the ease of use with respect to long term implant prognosis.
